CTOs on the Move

Sebastian International Inc

www.sebastianprofessional.com

 
Sebastian International Inc is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

WellPet Humane

WellPet Humane Animal Hospital in Doraville, GA is a welcoming animal hospital providing high quality, affordable veterinary medicine to the pets of the Doraville community.

Barry`s

Barry`s game-changing fitness classes offer our global community, the OG #FitFam, the Best Workout in the World® -- a workout that is as effective as it is fun. Founded in 1998, Barry`s has led the fitness industry in innovation. Today, you can experience our signature Red Room in more than 70 studios across 10 countries, as well as in the comfort of your own home. Whether you`re sprinting, lifting, or riding, in-studio or at-home, we`re on a mission to inspire you to work(out) hard, have fun, find your strength, and be your best.

CareMore Health group

CareMore Health group is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Total Health Care

Total Health Care is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.